Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm
NCT06492798
Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients
Sponsor: Changhai Hospital
Conditions
Long COVID Post-Acute COVID-19 Syndrome
Interventions
umbilical cord mesenchymal stem cell
Updated 2 times since 2024 Last updated: Jul 7, 2024 Started: Sep 1, 2023 Primary completion: Jul 1, 2025 Completion: Aug 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1/PHASE2 trial investigates Long COVID and Post-Acute COVID-19 Syndrome and is currently actively recruiting participants. Changhai Hospital leads this study, which shows 2 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
2 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Changhai Hospital
Data source: Changhai Hospital
For direct contact, visit the study record on ClinicalTrials.gov .